Health and Fitness Health and Fitness
Wed, November 3, 2010
Tue, November 2, 2010
Mon, November 1, 2010
Sat, October 30, 2010
Fri, October 29, 2010
Thu, October 28, 2010
Wed, October 27, 2010
Tue, October 26, 2010
Mon, October 25, 2010
Sun, October 24, 2010
[ Sun, Oct 24th 2010 ] - Market Wire
Alcon Board Elects New Chairman
Sat, October 23, 2010
Fri, October 22, 2010
Thu, October 21, 2010
Wed, October 20, 2010
[ Wed, Oct 20th 2010 ] - Market Wire
STJ, AGAM, BAC, MDT, BSX
Tue, October 19, 2010
Mon, October 18, 2010
Sun, October 17, 2010
Sat, October 16, 2010
Fri, October 15, 2010
[ Fri, Oct 15th 2010 ] - Market Wire
ALGN, FCN, GOOG, SWY, GCI

Exelixis Announces November 4 Webcast of Third Quarter 2010 Financial Results Conference Call


//health-fitness.news-articles.net/content/2010/ .. rter-2010-financial-results-conference-call.html
Published in Health and Fitness on Tuesday, October 26th 2010 at 4:46 GMT by Market Wire   Print publication without navigation


SOUTH SAN FRANCISCO, Calif.--([ BUSINESS WIRE ])--Exelixis, Inc. (Nasdaq:EXEL) will release its third quarter 2010 financial results on Thursday, November 4, 2010 after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. ET/ 2:00 p.m. PT, in which Exelixis management will discuss the financial results and financial outlook, and will provide a general business update. The webcast may be accessed in the Event Calendar page under Investors at [ http://www.exelixis.com ].

An audio replay of the webcast will be available until 11:59 p.m ET/ 8:59 p.m. PT on December 4, 2010. Access numbers for the replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international), and the passcode is 94605525.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer and potentially other serious diseases. Currently, Exelixisa™ broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo. For more information, please visit the companya™s web site at [ http://www.exelixis.com ].

Exelixis and the Exelixis logo are registered U.S. trademarks.


Publication Contributing Sources